BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
read more...
Apr 10, 2018
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
read more...
Apr 03, 2018
BeiGene Appoints J. Samuel Su to its Board of Directors
read more...
Mar 05, 2018
BeiGene to Present at Upcoming Investor Conferences
read more...
Feb 28, 2018
BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results
read more...
Feb 27, 2018
BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China
read more...
Feb 09, 2018
BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium
read more...
Feb 07, 2018
BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
read more...
Feb 05, 2018
BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China
read more...
Feb 05, 2018
BeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers Symposium
read more...
Jan 31, 2018
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma
read more...
Jan 22, 2018
BeiGene Announces Closing of $800 Million Public Offering
read more...
Jan 17, 2018
BeiGene Announces Pricing of $750 Million Public Offering
read more...
Jan 16, 2018
BeiGene Announces Proposed Public Offering
read more...
Jan 09, 2018
BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
read more...
Jan 08, 2018
BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region
read more...
Jan 02, 2018
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma
read more...
Dec 18, 2017
BeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian Cancer
read more...
Dec 11, 2017
BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting
read more...
Dec 09, 2017
BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual Meeting
read more...
